MBX Biosciences (MBX) Operating Expenses (2023 - 2026)

MBX Biosciences has reported Operating Expenses for 4 years, with the latest figure at $27.3 million in Q1 2026.

• Quarterly Operating Expenses rose 2.77% year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.7 million (up 63.92% YoY) and the FY2025 annual result came in at $98.1 million, up 43.79% from the prior year.
• Operating Expenses advanced to $27.3 million in Q1 2026 per MBX's latest filing, from $25.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $27.3 million in Q1 2026 and troughed at $1.3 million in Q1 2024.
• A 4-year average of $13.5 million and a median of $10.9 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 87.25% in 2024, then soared 1959.7% in 2025.
• Over 4 years, Operating Expenses stood at $10.0 million in 2023, then surged by 86.27% to $18.6 million in 2024, then surged by 38.61% to $25.8 million in 2025, then advanced by 5.7% to $27.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $27.3 million, $25.8 million, and $23.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.